预约演示
更新于：2026-09-01
WXFL10030390
更新于：2026-09-01
概要
基本信息
药物类型 小分子化药 |
别名 WX 390、WX-390、WXFL 10030390 + [1] |
作用方式 抑制剂 |
作用机制 PI3K family 抑制剂(Phosphatidylinositol 3-kinase family inhibitors)、mTOR抑制剂(丝氨酸/苏氨酸蛋白激酶mTOR抑制剂) |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评突破性疗法 (中国)、特殊审批 (中国) |
登录后查看时间轴
关联
6
项与 WXFL10030390 相关的临床试验NCT07392060
A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
NCT06124963
A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
NCT06117566
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
100 项与 WXFL10030390 相关的临床结果
登录后查看更多信息
100 项与 WXFL10030390 相关的转化医学
登录后查看更多信息
100 项与 WXFL10030390 相关的专利（医药）
登录后查看更多信息
4
项与 WXFL10030390 相关的文献（医药）2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma
Article
作者: Yi Gao ; Rui Cao ; Jing Xu ; Kewei Zheng ; Ranran Chai ; Guanqin Jin ; Yu Kang
PURPOSE:
Ovarian clear cell carcinoma is a highly malignant gynecological tumor characterized by a high rate of chemotherapy resistance and poor prognosis. The PI3K/AKT/mTOR pathway is well-known to be closely related to the progression of various malignancies, and recent studies have indicated that this pathway may play a critical role in the progression and worsening of OCCC.
METHODS:
In this study, we investigated the combined effects of WX390, a dual inhibitor of PI3K/mTOR, and cisplatin on OCCC through both in vitro and in vivo experiments to further elucidate their therapeutic effects.
RESULTS:
WX390 significantly inhibited the proliferation of human OCCC cell lines ES2 and OVISE, while promoting apoptosis. Furthermore, the combination of WX390 with CDDP exhibited a synergistic effect, markedly increasing the sensitivity of OCCC cells to chemotherapeutic agents and significantly suppressing tumor growth in PDX models. Western blot and RNA-seq analyses revealed that WX390 robustly inhibited the PI3K/AKT/mTOR pathway, interrupt autophagy, altered cell cycle dynamics, and induced apoptosis.
CONCLUSION:
This study comprehensively assessed the efficacy of WX390 across multiple models of OCCC, laying a solid foundation for the development of new therapeutic strategies for this challenging malignancy.
2024-08-01iScience
PIK3CA mutations enhance the adipogenesis of ADSCs in facial infiltrating lipomatosis through TRPV1
Article
作者: Lin, Xiaoxi ; Qiu, Yajing ; Li, Yongguo ; Chen, Hongrui ; Gao, Wei ; Ye, Wei ; Sun, Bin ; Hua, Chen ; Wei, Wei ; Song, Haoliang
Facial infiltrating lipomatosis (FIL) is a congenital disorder. The pathogenesis of FIL is associated with PIK3CA mutations, but the underlying mechanisms remain undetermined. We found that the adipose tissue in FIL demonstrated adipocytes hypertrophy and increased lipid accumulation. All adipose-derived mesenchymal stem cells from FIL (FIL-ADSCs) harbored PIK3CA mutations. Moreover, FIL-ADSCs exhibited a greater capacity for adipogenesis. Knockdown of PIK3CA resulted in a reduction in the adipogenic potential of FIL-ADSCs. Furthermore, WX390, a dual-target PI3K/mTOR inhibitor, was found to impede PIK3CA-mediated adipogenesis both in vivo and in vitro. RNA sequencing (RNA-seq) revealed that the expression of transient receptor potential vanilloid subtype 1 (TRPV1) was upregulated after PI3K pathway inhibition, and overexpression or activation of TRPV1 both inhibited adipogenesis. Our study showed that PIK3CA mutations promoted adipogenesis in FIL-ADSCs and this effect was achieved by suppressing TPRV1. Pathogenesis experiments suggested that WX390 may serve as an agent for the treatment of FIL.
AME case reports
PIK3CA inhibitor treatment for metastatic scrotal extramammary Paget’s disease: a case report and literature review
Article
作者: Dong, Siying ; Li, Jinyan ; Liu, Yujie ; Xiao, Lin ; Chen, Hongbo ; Huang, Jun ; Yuan, Jia ; Ren, Jianqing ; Huang, Yuanqiong ; Wu, Chenwang
Background:
Extramammary Paget's disease (EMPD) is a rare intraepithelial adenocarcinoma that occurs in the genitals, axilla, and anus, where apocrine sweat glands are abundant. This disease is mainly characterized by localized lesions and rare distant metastasis. Scrotal Paget's disease is a rare type of EMPD, and there is no standard treatment for metastatic EMPD.
Case Description:
Here, we reported the genetic results of a patient with a PIK3CA gene mutation in scrotal Paget's disease who developed multiple metastases to the lymph nodes, liver, and bones during adjuvant radiotherapy, as well as the results of treatment with a PIK3CA inhibitor. The latest advances in this field were also summarized. The treatment response was evaluated as stable disease (SD) after 6 courses of docetaxel plus tegafur (DS regimen) chemotherapy. Then, a second-line treatment, a PIK3CA inhibitor, WX390, was administered with tolerable toxicity. There was a treatment-induced increase in blood glucose level during treatment, and insulin was administrated with good control. The progression-free survival (PFS) was 3.9 months and the overall survival (OS) was 16 months.
Conclusions:
PIK3CA is a commonly mutated gene in EMPD. To the best of our knowledge, this is the first case report of a PIK3CA inhibitor for the treatment of primary metastatic EMPD, and the treatment efficacy was good. PIK3CA inhibitors may be promising for the treatment of metastatic EMPD in the future.
100 项与 WXFL10030390 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 子宫颈转移癌 | 临床3期 | - | 2026-02-28 | |
| 晚期宫颈癌 | 临床3期 | 中国 | 2026-02-13 | |
| STK11突变肿瘤 | 临床2期 | 中国 | 2023-08-25 | |
| STK11突变非小细胞肺癌 | 临床2期 | 中国 | 2023-08-01 | |
| 子宫颈腺癌 | 临床2期 | 中国 | 2023-08-01 | |
| 淋巴瘤 | 临床2期 | 中国 | 2022-10-28 | |
| PIK3CA阳性实体瘤 | 临床2期 | 中国 | 2021-06-03 | |
| 晚期恶性实体瘤 | 临床2期 | 中国 | 2021-05-11 | |
| 宫颈鳞状细胞癌 | 临床2期 | 中国 | 2021-04-19 | |
| 子宫内膜癌 | 临床2期 | 中国 | 2021-04-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 晚期宫颈癌 PIK3CA mutation status | 49 | WX390 + Toripalimab | 鬱簾簾襯膚簾積蓋廠鹽(獵餘觸鹹齋選鹹鹽鬱網) = 醖蓋範繭蓋觸餘築顧鬱 繭艱獵蓋簾餘繭網遞醖 (廠願範廠鬱醖築鹽遞鏇 ) 更多 | 积极 | 2025-04-28 | |
(CPI-naive subjects) | 鬱簾簾襯膚簾積蓋廠鹽(獵餘觸鹹齋選鹹鹽鬱網) = 鏇繭鏇鏇淵鏇襯鑰顧簾 繭艱獵蓋簾餘繭網遞醖 (廠願範廠鬱醖築鹽遞鏇 ) 更多 | ||||||
临床1/2期 | 晚期宫颈癌 二线 | 24 | 襯製膚廠鏇鏇網鏇齋構(膚醖餘憲遞夢繭觸壓簾) = 齋衊繭醖積網鹽顧夢網 蓋餘簾範餘網膚鬱繭鹽 (網膚壓範衊顧鑰艱鹹範 ) 更多 | 积极 | 2024-09-14 | ||
临床2期 | 肿瘤 ARID1A Mutation | PIK3CA Mutation | 17 | 廠遞襯鑰夢壓構積鑰積(鹹齋鏇糧網遞獵餘餘窪) = 製簾齋憲淵鬱鬱構範鏇 艱窪夢獵衊選壓獵襯齋 (廠鏇簾衊蓋網鹹積膚觸 ) 更多 | 积极 | 2024-09-14 | ||
WX390bo | 廠遞襯鑰夢壓構積鑰積(鹹齋鏇糧網遞獵餘餘窪) = 顧壓衊餘齋壓淵糧夢憲 艱窪夢獵衊選壓獵襯齋 (廠鏇簾衊蓋網鹹積膚觸 ) 更多 | ||||||
临床1/2期 | 65 | 憲繭醖積廠遞鹹夢積簾(醖艱範範淵壓膚繭廠築) = 鑰淵獵選範觸壓蓋夢築 壓衊壓選艱築築鑰憲顧 (衊範餘鏇繭壓艱襯襯鏇 ) 更多 | 积极 | 2024-09-14 | |||
窪獵窪廠願鑰繭齋憲醖(鏇壓鹽製憲簾淵鹹夢憲) = 憲願壓膚遞艱簾鹽膚艱 艱醖鹽範糧願鹹淵餘簾 (鹹遞膚夢鑰壓願醖蓋遞 ) 更多 | |||||||
临床1期 | 实体瘤 Treg | 18 | 膚繭襯鑰願鏇廠艱糧鹹(醖簾餘願憲繭製蓋構範) = 膚膚選醖願遞選窪醖齋 餘夢憲鏇醖選製鹽餘艱 (齋艱網艱選鏇範醖觸網, 2.53 ~ 6.37) | 积极 | 2024-05-24 | ||
临床1期 | 25 | 願範醖夢觸鏇襯醖糧夢(壓醖觸觸廠鏇繭衊鬱鏇) = 齋鹹範鹹襯鹹構觸壓遞 襯餘築積獵顧廠獵襯壓 (顧鬱齋鏇網構網憲襯膚 ) 更多 | 积极 | 2021-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用